CD19 and neoplasm: Deniger et al. reported that polyclonal γδ T cells with CD19-specific CAR-γδ T cells enhanced killing of CD19+ tumor cells compared with CARneg γδ T cells in vitro, and CD19-specific CAR-γδ T cells reduced CD19+ leukemia xenografts in mice [136].